Eric Widera News Today

Food and Drug Administration approved Leqembi last year

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.

(Repeats to additional subscribers with no changes to text ) By Julie Steenhuysen CHICAGO (Reuters) -Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle...

Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimers, Eisai and Biogens Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among some doctors that treating the memory-robbing disease is futile.

CHICAGO (Reuters) -Nine months into the U.S. launch of the first drug proven to slow the advance of Alzheimer's, Eisai and Biogen's Leqembi is facing an unexpected hurdle to widespread use: an entrenched belief among some doctors that treating the memory-robbing disease is futile. Alzheimer's experts had anticipated bottlenecks due to Leqembi's requirements, which include additional diagnostic tests, twice-monthly infusions and regular brain scans to guard against potentiall...

The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected ...

The adoption of the FDA-approved Alzheimer's drug, Leqimbi, has slowed down in the U.S. as more experts grow hesitant about the drugs cost, risks and efficacy.

The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it

The Food and Drug Administration gave Leqembi full approval last summer for patients with early stages of the disease. But sales have lagged.

NEW YORK (TNS) — A few years ago, researchers made the unnerving discovery that in the brains of people with Alzheimer’s disease, disordered clumps of abnormal proteins had been growing